Edimer: Gland idea

Edimer aims to test fusion protein in newborns with rare X-linked disorder

Unlike enzyme replacement therapies that are taken chronically for life, Edimer Pharmaceuticals Inc. hopes a single course of its EDI200 given either before or soon after birth will permanently correct a rare developmental disorder. The fusion protein entered human testing this year and the company hopes to achieve clinical proof of concept in mid-2014.

X-linked hypohidrotic ectodermal dysplasia (XLHED) is a developmental disorder caused by the absence of ectodysplasin A, a protein required for proper formation of glandular structures in the skin.

The condition is characterized by an inability

Read the full 879 word article

How to gain access

Continue reading with a
two-week free trial.